ArticleClinicoEconomics and outcomes research : CEOR2025

Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy.

Luca Prosperini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.